|
|
Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/1631
|
| Title: | Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial |
| Authors: | Ssali, Francis
Stöhr, Wolfgang
Munderi, Paula
Reid, Andrew
Walker, A Sarah
Gibb, Diana M
Mugyenyi, Peter
Kityo, Cissy
Byakwaga, Helen
Katabira, Elly
Darbyshire, Janet H
Gilks, Charles F |
| Keywords: | Prevalence
HIV/AIDS
CD4 count
Zidovudine regimens
Antiretrovial Therapy
Anaemia
Lower haemoglobin
Zimbabwe
Uganda
T-cells |
| Issue Date: | 2006 |
| Publisher: | International Medical Press |
| Citation: | Ssali, F., Stöhr, W., Munderi, P., Reid, A., Walker, A.S., Gibb, D.M., Mugyenyi, P., Kityo, C., Byakwaga, H., Katabira, E., Darbyshire, J.H., Gilks, C.F. (2006). Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antiviral Therapy, 11 |
| Abstract: | Objective: To describe the prevalence, incidence and predictors of severe anaemia in previously untreated symptomatic HIV-infected adults with CD4+ T-cells <200 cells/mm3 initiating zidovudine-containing regimens in Africa.
Design: DART is a randomized trial comparing two strategies for HIV/AIDS management in Uganda and Zimbabwe.
Methods: We analysed the occurrence of anaemia at weeks 4 and 12, and then every 12 weeks. We also evaluated sex, age, WHO stage, body mass index (BMI), baseline laboratory measurements and first regimen as predictors of developing grade 4 anaemia (<6.5 mg/dl) by week 48 using logistic regression.
Results: To May 2005, 3,314 participants (65% women, 23% at WHO stage 4, median age=37 years, baseline CD4+ T-cell=86 cells/mm3 and median baseline haemoglobin = 11.4 g/dl) had a median 72 weeks follow-up. Prevalence of grade 4 anaemia was 0.7%, 2.0%, 0.5% and <0.5% at weeks 4, 12, 24 and ≥36, respectively. Overall, 219 (6.6%) participants developed grade 4 anaemia by week 48; women and those with lower haemoglobin, CD4+ T-cell count and BMI at baseline were at significantly higher risk (P<0.05), but not those with lower neutrophils or receiving cotrimoxazole at baseline.
Conclusions: We observed a higher incidence of grade 4 anaemia than in studies from industrialized countries, which is likely to be due in part to population characteristics and in part to a higher rate of concurrent HIV-related clinical events. Clinical vigilance and haemoglobin measurements 4, 8 and 12 weeks after starting zidovudine could help to manage serious anaemia. |
| URI: | http://hdl.handle.net/123456789/1631 |
| ISSN: | 1359-6535 |
| Appears in Collections: | Research Articles (Health-Sciences)
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| Ssali-Chs-Res.pdf | | 543Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
